Hammersmith Medicines Research

Hammersmith Medicines Research (HMR) is the UK's largest Phase 1 clinical research organization, holding MHRA Phase 1 accreditation and a Home Office licence for controlled drug substances including psychedelics. HMR led the Phase I/IIa clinical trial of SPL026 (DMT fumarate) for major depressive disorder on behalf of Small Pharma, positioning it as a leading UK site for early-phase psychedelic medicine trials.